Found 11 matching trials
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer PHASE1 This phase I trial is studying the side effects and best dose of TLR8 agoni...
Show More Location
Gynecologic Oncology Group of Arizona
Learn More & Join Trial
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck PHASE2 The purpose of this study is to compare the progression-free survival of pa...
Show More Location
University of Arkansas for Medical Sciences
Learn More & Join Trial
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab PHASE1 Protocol VRXP-A106 will enroll patients with Stage II-IVA head and neck can...
Show More Location
University of Pittsburgh Medical Center
Learn More & Join Trial
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer PHASE1 This is a multi-center, Phase I study of a new investigational drug, VTX-23...
Show More Learn More & Join Trial
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer PHASE1 This is an open label, Phase 1b pre-operative window of opportunity biomark...
Show More Location
Local Institution - 112
Learn More & Join Trial
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas PHASE1 This study is to determine the safety and effectiveness of VTX-2337 (an inv...
Show More Location
Stanford Cancer Center
Learn More & Join Trial
Intratumoral Microdosing of Motolimod in HNSCC EARLY_PHASE1 This is a multi-center, single arm, open-label, multi-agent, localized phar...
Show More Location
University of California, San Francisco
Learn More & Join Trial
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer PHASE1 This is an ongoing Phase 1/2, open-label, multicenter, non-randomized study...
Show More Location
Research Facitlity
Learn More & Join Trial
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck PHASE1 This phase I trial studies the side effects and best dose of TLR8 Agonist V...
Show More Location
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Learn More & Join Trial
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer PHASE2 The purpose of this study is to compare the overall survival of patients tr...
Show More Location
St. Joseph's Hospital and Medical Center
Learn More & Join Trial